The STOP-HER2 TBCRC062 Trial:Outcomes in Patients with HER2+ Metastatic Breast Cancer - Clinical Trial
What is the Purpose of this Study?
Estamos realizando este estudio para averiguar si el tratamiento anti-HER2 se puede detener de forma segura en pacientes con cáncer de mama HER2+ metastásico que han tenido una respuesta excepcional al tratamiento durante al menos 3 años.
Cáncer de mama metastásico HER2+
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with metastatic HER2+ breast cancer
- Have been on first-line anti-HER2 therapy for at least 3 years
- Have not had any disease progression
For more information about who can join this study, please contact the study team at breastcl@dm.duke.edu.
What is Involved?
Si elige unirse a este estudio, podrá:
- Make a choice to participate in 1 of 2 groups
-- You can continue to receive the anti-HER2 therapy you are taking; OR
-- You can stop taking anti-HER2 therapy
- Realizar extracciones de sangre
- Hacerse estudios de imágenes
- Completar cuestionarios
- Danos permiso para usar tus muestras de tejido almacenadas
Study Details
